Premium
The prognostic significance of the insulin‐like growth factor‐1 ligand and receptor expression in breast cancer tissue
Author(s) -
Chong Kelvin Y.M.,
Subramanian Ashok,
Mokbel Kefah,
Sharma Anup K.
Publication year - 2011
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21916
Subject(s) - medicine , breast cancer , cancer , oncology , insulin like growth factor , messenger rna , receptor , growth factor , biology , gene , biochemistry
Background and Objectives Previous in vitro studies have suggested that IGF‐1 stimulation can lead a more aggressive breast cancers and subsequent poor prognosis in breast cancer patients. We aim to how IGF‐1 and IGF‐1R mRNA levels in breast cancer are associated with disease‐free survival (DFS) and other clinicopathological factors. Methods IGF‐1 and IGF‐1R mRNA levels were measured in breast cancer tissue from 132 patients using real‐time PCR. DFS and clinicopathological information were obtained from patient case notes. Results IGF‐1 and IGF‐1R mRNA levels did not correlate with any clinicopathological factors. Patients who relapsed had lower IGF‐1 mRNA levels in their tumour tissue compared to those who remained disease‐free during the 5‐year follow‐up period. Patients who had ER‐positive breast cancers with high IGF‐1 mRNA levels had longer DFS compared to those with low IGF‐1 mRNA levels. IGF‐1 mRNA levels was not associated with DFS in patients with ER‐negative cancers. IGF‐1R mRNA levels was not associated with DFS in any subgroup analysis. Multivariate analysis showed that IGF‐1 mRNA levels and histopathological grade were independent predictors of DFS. Conclusions Breast cancer tissue IGF‐1 expression is a favourable prognostic indicator and could be used in clinical setting in planning for adjuvant treatment. J. Surg. Oncol. 2011; 104:228–235. © 2011 Wiley‐Liss, Inc.